Ads
related to: nintedanib for ipf 3 mg tablet- Your Treatment Plan
Find Out If It Fits
in Your Plan
- How It Helps
Discover How OFEV®
May Help Patients
- Dosing Information
Learn More About
Taking OFEV
- Savings Card
Patient Support Program
Help With Your Questions
- Your Treatment Plan
Search results
Results from the WOW.Com Content Network
Nintedanib was approved for idiopathic pulmonary fibrosis on 15 October 2014, by the United States Food and Drug Administration (FDA), [30] and received a positive opinion from the European Medicines Agency in November 2014, being approved in the European Union in January 2015.
Patients with idiopathic pulmonary fibrosis were randomly assigned to treatment with oral pirfenidone or placebo for a minimum of 72 weeks. [47] In study 004, pirfenidone reduced decline in forced vital capacity. Mean change in FVC at week 72 was –8.0% in the pirfenidone 2403 mg/day group and –12.4% in the placebo group, a difference of 4.4%.
[3] [12] A recent study from the US estimated the incidence of IPF to be between 6.8 and 16.3 per 100,000 persons. In the 27 European Union countries, a range of sources estimate an incidence of 4.6–7.4 people per 100,000 of the population, [ 73 ] [ 74 ] suggesting that approximately 30,000–35,000 new patients will be diagnosed with IPF ...
[1] [3] [6] But in most cases the cause is unknown (idiopathic pulmonary fibrosis). [1] [3] Diagnosis may be based on symptoms, medical imaging, lung biopsy, and lung function tests. [1] No cure exists and treatment options are limited. [1] Treatment is directed toward improving symptoms and may include oxygen therapy and pulmonary rehabilitation.
The strategy of development of setanaxib was initially focused on the treatment of fibrosis and particularly idiopathic pulmonary fibrosis (IPF). Setanaxib obtained orphan drug designation from regulatory agencies in the US and EU in early 2010. [12] It was later granted FDA Fast Track Designation in PBC in August 2021. [13]
Ziritaxestat is a small-molecule, selective autotaxin inhibitor that was investigated as a potential treatment for idiopathic pulmonary fibrosis (IPF). [1] Initially showing promise in early-phase studies, ziritaxestat underwent evaluation in two large-scale phase 3 clinical trials, ISABELA 1 and ISABELA 2.
Admilparant is an investigational new drug being developed by Bristol-Myers Squibb for the treatment of idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF). It is a first-in-class lysophosphatidic acid receptor 1 (LPA1) antagonist. [1] [2] As of 2024, admilparant is in Phase III clinical trials for both IPF and PPF. [2] [3]
They have also been used to treat other diseases, such as idiopathic pulmonary fibrosis. They are also called tyrphostins, the short name for "tyrosine phosphorylation inhibitor", originally coined in a 1988 publication, [1] which was the first description of compounds inhibiting the catalytic activity of the epidermal growth factor receptor ...
Ads
related to: nintedanib for ipf 3 mg tablet